From: A multidisciplinary approach to screen the post-COVID-19 conditions
Number of SC | N. of patients with SC at discharge | Number of patients by SC present at discharge still present at follow-up | |||
---|---|---|---|---|---|
0 | 1 | 2 |  ≥ 3 | ||
0 | 44 (12.2) | 44 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
1 | 99 (27.4) | 41 (41.4) | 58 (58.6) | 0 (0.0) | 0 (0.0) |
2 | 100 (27.7) | 24 (24.0) | 33 (33.0) | 43(43.0) | 0 (0.0) |
 ≥ 3 | 118 (32.7) | 9 (7.6) | 12 (10.2) | 37 (31.4) | 60 (50.8) |
TOTAL | 361 (100) | 118 (32.7) | 103 (28.5) | 80 (22.2) | 60 (16.6) |
 | N. of patients with SC developed during follow up | Number of patients by SC developed during follow-up, still present at follow-up visit | |||
---|---|---|---|---|---|
0 | 1 | 2 |  ≥ 3 | ||
0 | 202 | 202 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
1 | 116 | 26 (22.4) | 90 (77.6) | 0 (0.0) | 0 (0.0) |
2 | 39 | 3 (7.7) | 3 (7.7) | 33 (84.6) | 0 (0.0) |
 ≥ 3 | 4 | 0 (0.0) | 0 (0.0) | 2 (50.0) | 2 (50.0) |
TOTAL | 361 | 231 (64.0) | 93 (25.8) | 35 (9.7) | 2 (0.5) |